Skip to main content

CORRECTION article

Front. Mol. Biosci., 25 June 2024
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 | https://doi.org/10.3389/fmolb.2024.1444446

Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

This article is a correction to:

  1. Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

    1. Read original article
Andrea Vannini,Andrea Vannini1,2Federico ParentiFederico Parenti1Cristina ForghieriCristina Forghieri1Catia BarboniCatia Barboni3Anna ZaghiniAnna Zaghini3Gabriella Campadelli-Fiume &#x;Gabriella Campadelli-Fiume1*†Tatiana Gianni &#x;Tatiana Gianni1*†
  • 1Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
  • 2Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
  • 3Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy

A Corrigendum on
Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

by Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G and Gianni T (2023). Front. Mol. Biosci. 10:1149973. doi: 10.3389/fmolb.2023.1149973

In the published article, the Reference for Lopez and Olive, 2020 was incorrectly written as “Lopez, M., and Olive, D. (2020). Antibodies having specificity to nectin-4 and uses thereof. Google Patents”. It should be “Lopez, M. (2018) Antibodies having specificity to nectin-4 and uses thereof. Google Patents.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: oncolytic virus, oncolytic herpes simplex virus, retargeting, nectin4, anti-cancer vaccine, immunotherapy, pancreas carcinoma, triple negative breast cancer

Citation: Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G and Gianni T (2024) Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers. Front. Mol. Biosci. 11:1444446. doi: 10.3389/fmolb.2024.1444446

Received: 05 June 2024; Accepted: 06 June 2024;
Published: 25 June 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Vannini, Parenti, Forghieri, Barboni, Zaghini, Campadelli-Fiume and Gianni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Gabriella Campadelli-Fiume, Z2FicmllbGxhLmNhbXBhZGVsbGlAdW5pYm8uaXQ=; Tatiana Gianni, dGF0aWFuYS5naWFubmkzQHVuaWJvLml0

†These authors have contributed equally to this work and share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.